Myriad Genetics (NASDAQ:MYGN) Downgraded by Wall Street Zen to Sell

Posted by George Bondi on Aug 9th, 2026

Wall Street Zen cut shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a hold rating to a sell rating in a report published on Saturday morning.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their price objective on Myriad Genetics from $5.50 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, August 3rd. Zacks Research downgraded shares of Myriad Genetics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 4th. Weiss Ratings lowered shares of Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. Finally, TD Cowen lowered their price target on shares of Myriad Genetics from $6.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, July 31st. One analyst has rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $5.38.

Get Our Latest Report on Myriad Genetics

Myriad Genetics Price Performance

NASDAQ MYGN opened at $3.26 on Friday. The company has a market cap of $311.82 million, a PE ratio of -2.74 and a beta of 1.69. The firm’s 50 day moving average price is $5.01 and its 200-day moving average price is $4.83. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. Myriad Genetics has a 52-week low of $2.74 and a 52-week high of $8.59.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.19). The business had revenue of $190.70 million during the quarter, compared to the consensus estimate of $206.03 million. Myriad Genetics had a negative return on equity of 16.09% and a negative net margin of 13.96%.The business’s quarterly revenue was down 10.5% on a year-over-year basis. During the same period last year, the firm earned $0.05 EPS. Sell-side analysts forecast that Myriad Genetics will post -0.62 EPS for the current fiscal year.

Insider Transactions at Myriad Genetics

In other Myriad Genetics news, Director Paul Bisaro purchased 7,500 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $3.69 per share, for a total transaction of $27,675.00. Following the completion of the purchase, the director owned 97,441 shares in the company, valued at $359,557.29. This represents a 8.34% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rashmi Kumar sold 15,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $4.46, for a total value of $66,900.00. Following the sale, the director owned 171,889 shares in the company, valued at $766,624.94. The trade was a 8.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.90% of the company’s stock.

Institutional Trading of Myriad Genetics

Large investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Myriad Genetics by 2,333.3% in the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock worth $25,000 after buying an additional 4,480 shares during the last quarter. Quarry LP increased its position in shares of Myriad Genetics by 155.6% in the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after acquiring an additional 2,657 shares during the period. Royal Bank of Canada increased its position in shares of Myriad Genetics by 129.6% in the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after acquiring an additional 2,818 shares during the period. Raymond James Financial Inc. purchased a new position in Myriad Genetics in the 2nd quarter worth $37,000. Finally, American Century Companies Inc. purchased a new position in Myriad Genetics in the 2nd quarter worth $55,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

About Myriad Genetics

(Get Free Report)

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.